All posts by imreal

Organizations Rise Above eDiscovery Challenges with Information Governance and Technology


eDiscovery Challenges

Common eDiscovery challenges often make the process overwhelming, but proactive information governance and wise use of available technology can help.

eMazzanti Technologies, a NYC area information governance expert and MSP encourages organizations to rise above eDiscovery challenges in a new article on the eGovernance.com website. The informative article first asserts that eDiscovery data must be collected from many different types of files and data environments.

The author shares that the right tools enable legal teams to locate and assess the data in place before collecting anything and to complete an early data assessment. He then asserts that the team must use defensible methods to collect and preserve data, including legal holds. He concludes by urging readers to ensure data security by keeping sensitive data in house.

“Each year, organizations spend countless hours and millions of dollars conducting eDiscovery for pending litigation, FOIA requests, audits and more,” related Greg Smith, Vice President of Services Delivery at eGovernance. “Common eDiscovery challenges often make the process overwhelming, but proactive information governance and wise use of available technology can help.”

Below are a few excerpts from the article, “Rise Above eDiscovery Challenges with Information Governance and Technology.”

Collect Massive Amounts of Data from Disparate Sources

“Civil and criminal cases frequently hinge on digital evidence, and that can mean data requests involving millions of document files. With modern collaboration methods, those documents include everything from email and voicemail to word processing files, social media and more.”

“In addition to including many different types of files, eDiscovery must also address numerous data environments. For instance, employees may use both company-owned and personal devices, from laptops to phones and tablets. Additionally, the organization may store data both on-premises and in multiple cloud environments and numerous applications.”

Prevent Digital Spoliation of Evidence

“While gathering these massive amounts of data, legal teams must take care to prevent destruction of or tampering with relevant data. This includes altering or deleting documents in any way. Whether intentional or not, this destruction of evidence, or spoliation, can result in stiff penalties and cause enormous problems.”

Ensure Data Security

“When organizations collect huge amounts of data and send it outside the organization, they effectively lose control of that data. Consider the thumb drives and other copies of data held by opposing counsel and expert witnesses. Every copy of the data distributed represents a cyber security risk.”

eDiscovery Solution to Address eDiscovery Challenges

Locating, collecting, and preserving data in a defensible way can prove difficult and time consuming when organizations do not have control of their data. And because of the amount of data and the time involved, eDiscovery costs typically represent from 20 to 50 percent of the costs of litigation.

eGovernance provides a comprehensive eDiscovery solution to reduce discovery overhead and improve the speed and efficiency of managing requests across disparate systems. Its unique tools allow organizations to centralize eDiscovery. Whether legal counsel reviews data in place or extracts copies for more resilient retention requirements, the data stays secure.

Have you read?

2023 Information Governance Trends Driving Business Strategy

Reduced Risk and Lower Costs Highlight the Benefits of Compliance Technology

About eMazzanti Technologies

eMazzanti’s team of trained, certified IT experts rapidly deliver increased revenue growth, data security and productivity for clients ranging from law firms to high-end global retailers, providing advanced cyber security, information governance, retail and payment technology, cloud and mobile solutions, multi-site implementations, 24×7 outsourced network management, remote monitoring, and support.

eMazzanti has made the Inc. 5000 list 9X, including eight consecutive years, is a 4X Microsoft Partner of the Year, the #1 ranked NYC area MSP and NJ Business of the Year! Contact: 1-866-362-9926, info@emazzanti.net or http://www.emazzanti.net Twitter: @emazzanti Facebook: Facebook.com/emazzantitechnologies.

Share article on social media or email:

123Loadboard Adds Carrier Identity Verification to Streamline and Accelerate Digital Freight Booking


123Loadboard

Our load board platform has always revolved around trust. Verifying the information our customers provide is a vast undertaking, but it fits our company’s aspirations of ensuring all users are offered quality data so that they can feel confident that their transactions are credible and secure.

123Loadboard, a leading freight matching platform, confirmed today that carrier identity verification is available on their platform to help brokers move freight faster with trusted carriers. This move to add identity verification to available carrier data is the latest part of an ongoing effort to bring additional transparency to freight brokers.

Carriers using 123Loadboard’s freight matching platform go through an updated carrier verification process to confirm their identity, after which a confirmed identity icon is displayed to freight brokers on the carriers’ profile. Brokers and shippers can immediately identify whether the carrier to whom they wish to assign the load is verified and a legitimate business partner.

“Our focus has always been to provide decision-makers with better data and this latest initiative helps freight brokers move loads through instant booking while reducing fraud and minimizing their risk when assigning available freight, without the need to interact with third-party sites for carrier identity validation,” says Loarn Metzen, Co-founder, 123Loadboard.

Freight brokers and shippers seeking capacity can match their loads and search 123Loadboard’s Truck Locator for verified carriers that match their required hauling criteria and be assured that the identified individuals have not misrepresented themselves. 123Loadboard confirms that identity verification adds credibility to member profiles and will in turn improve the freight brokers’ and shippers’ reliability when dealing with current or future clients.

“123Loadboard’s identity verification system saves time, effort, and energy by allowing customers to be sure of the other party’s identity before running further checks on their reputation”, Loarn continues.

Freight brokers interacting on 123Loadboard or integrated directly through API, whether by messaging, bidding, emailing, etc., will see the verification status of the carriers they communicate with. The convenience factor of the validation will provide the trustworthy, streamlined experience 123Loadboard users have come to expect.

“Our load board platform has always revolved around trust. Verifying the information our customers provide is a vast undertaking, but it fits our company’s aspirations of ensuring all users are offered quality data so that they can feel confident that their transactions are credible and secure,” says Rafi Hagopian, Head of Product, 123Loadboard.

In the near future, 123Loadboard users will be able to transfer their verification status across partner platforms to standardize and increase transparency beyond 123Loadboard and into the logistics ecosystem. This milestone will allow partner apps to prompt carriers to verify their 123Loadboard identity and transfer their data. The verification status would also be displayed on the partners’ platform once completed.

123Loadboard confirms that carrier identity verification will add more credibility to its freight matching marketplace as the company focuses on improving user experience to maintain its position as the highest-rated load board app in the trucking industry. Providing enhanced functionality of this nature is key to enabling the freight brokers that post their available loads to make more informed decisions, ensuring that their clients’ cargo is in good hands and will be delivered safely and on time.

About 123Loadboard

123Loadboard provides a freight-matching marketplace for carriers, owner-operators, brokers, and shippers to engage with pertinent, easy-to-use tools using the latest technologies to help professional truck drivers find loads and increase their loaded miles. Affordable web and mobile apps allow users to customize their subscriptions to meet their specific needs. The company is a trusted source for freight matching, credit, compliance issues, and mileage. Learn more at http://www.123Loadboard.com.

Media Contact

Jennepher Hunter

Phone: (437) 887-2848

Email: mailto:jennepher.hunter@123loadboard.com [jennepher.hunter@123loadboard.com __title__ jennepher.hunter@123loadboard.com]

Share article on social media or email:

NeuroCytonix Completes Clinical Trial of its NeuroCytotron Treatment of Cerebral Palsy


NeuroCytonix Logo

NeuroCytonix Completes Clinical Trial of its NeuroCytotron Treatment of Cerebral Palsy

NeuroCytonix, Inc. (the “Company” or “NeuroCytonix”) today announced that on January 19, 2023, its subsidiary NeuroCytonix Mexico has received a regulatory acknowledgment letter from the Mexican regulatory authority COFEPRIS – ref/memorandum number 223300ES450795/2023 – following the presentation of NeuroCytonix final report on its clinical trial on Cerebral Palsy NCX-CP-01.

COFEPRIS is member of the International Council of Harmonization (ICH) and Pharmaceutical Inspection Cooperation Scheme (PIC/S). In addition, COFEPRIS is a Level IV: National Regulatory Authority competent and efficient in the performance of the health regulatory functions recommended by PAHO / WHO.

The acknowledgment represents the legal and formal conclusion of the clinical trial, according to the methodology authorized by COFEPRIS. The resolution of the NCX-CP-01 clinical trial provides safety and efficacy data on investigational NeuroCytotron treatment of Cerebral Palsy. A manuscript detailing the results of this clinical trial is currently under preparation and will soon be submitted to several scientific journals.

The results of this clinical trial provide support for additional studies that will continue to evaluate the ongoing application of therapies with the NeuroCytotron in larger groups of patients, which will be supported by a Standard Operating Procedure where all cases will be recorded. This acknowledgment confirms that NeuroCytonix is ​​a company that has formally concluded a clinical trial for its investigational NeuroCytotron treatment and is now registered in the National Registry of Research Companies in Mexico.

About NeuroCytonix

NeuroCytonix is an emerging biotechnology business founded in January 2017 by Dr. J Roberto Trujillo to develop and exploit transformational medical technologies for the regeneration of the nervous system. The Company’s technology and related protocols include Stroke, Autism, Cerebral Palsy and neurological consequences of Traumatic Brain Injury (TBI) and Covid19. The Company’s core technology, the NEUROCYTOTRON, utilizes non-invasive, safe, tissue engineering technology that stimulates proteins which aid in the regeneration of brain cells.

The NeuroCytonix technology is based on the work of Dr. Rajah V Kumar, inventor of the Cytotron and a pioneer for more than 30 years in the field of biophysics, radiobiology, and regenerative tissue engineering.

The NeuroCytonix founder and CEO, Dr. J. Roberto Trujillo, an MD and PhD from Harvard University, is a leader in clinical and basic neuroscience research and molecular virology for brain diseases and is transforming the status quo of healthcare for these previously believed incurable conditions.

NeuroCytonix has built a Research Center in Monterrey Mexico where it has trained and directed a clinical research team who has successfully implemented its first Cerebral Palsy clinical trial evaluating the safety and efficacy of the treatment.

Link to the full study on ClinticalTrials.gov.

Please visit http://www.neurocytonix.com for more information.

Contact:

Laurent Lavigne du Cadet

Chief Financial Officer

llavigne@neurocytonix.com

Share article on social media or email:

Juno Diagnostics’ Co-Founder and CEO, Dirk van den Boom, Accepted into Forbes Business Council


News Image

As a co-founder and CEO, this gives me the opportunity to connect with others on their perspectives related to women’s healthcare, diagnostics, genetic testing solutions, and the overall landscape of the medical industry.

Juno Diagnostics™, Inc. (JunoDx™), a women’s health company focused on improving equitable access to prenatal care led by industry experts, announced today that its co-founder and CEO, Dirk van den Boom, has been accepted into the Forbes Business Council, an invitation-only community for successful business owners and leaders worldwide.

Dr. Van den Boom was vetted and selected by a review committee based on the depth and diversity of his experience. Criteria for acceptance include a track record of successfully impacting business growth metrics, as well as personal and professional achievements and honors.

“We are honored to welcome Dirk van den Boom into the community,” said Scott Gerber, founder of Forbes Councils, the collective that includes Forbes Business Council. “Our mission with Forbes Councils is to bring together proven leaders from every industry, creating a curated, social capital-driven network that helps every member grow professionally and make an even greater impact on the business world.”

As an accepted member of the Council, Dr. Van den Boom has access to a variety of exclusive opportunities designed to help him reach peak professional influence. He will connect and collaborate with other respected local leaders in a private forum and at members-only events. Van den Boom will also be invited to work with a professional editorial team to share his expert insights in original business articles on Forbes.com, and to contribute to published Q&A panels alongside other experts.

Finally, Dr. Van den Boom will benefit from exclusive access to vetted business service partners, membership-branded marketing collateral, and the high-touch support of the Forbes Councils’ member concierge team.

“I am thrilled to be asked to join the Forbes Business Council,” said Dr. Van den Boom. “As a co-founder and CEO, this gives me the opportunity to connect with others on their perspectives related to women’s healthcare, diagnostics, genetic testing solutions, and the overall landscape of the medical industry. Juno Diagnostics will only continue to grow these partnerships and secure our role as a leading women’s health company that provides equitable access to prenatal care.”

About Forbes Councils

Forbes Councils is a collective of invitation-only communities created in partnership with Forbes and the expert community builders who founded the Young Entrepreneur Council (YEC). In Forbes Councils, exceptional business owners and leaders come together with the people and resources that can help them thrive.

To learn more about Forbes Councils, visit forbescouncils.com.

About Juno Diagnostics™

Juno Diagnostics™ is a category-defining health company bringing vital prenatal health information to patients by combining accessibility, affordability, and transparency. The Company has developed a proprietary Sample Collection Kit and Device to facilitate capillary blood-based testing. Its lead product, the Juno Hazel™ test, is a non-invasive prenatal screening (NIPS) test that utilizes the proprietary Sample Collection Kit and improves access to high-quality testing results without the high cost, long lead times, and phlebotomy requirements of traditional NIPS.

For more information, visit http://www.junodx.com and engage with us on LinkedIn.

Share article on social media or email:

International Health Insurance for Digital Nomads


Genki, the health and insurtech startup focused on digital nomads, is proud to announce Genki World Resident, an innovative international health insurance plan designed specifically for long-term digital nomads and nomad families.

Genki World Resident is a comprehensive health insurance plan that covers the cost of medically necessary treatment and preventive care around the world. It is available to people of all ages and from any country, regardless of citizenship or residence.

“With Genki World Resident, digital nomads no longer have to choose between traveling the world and taking great care of their health.” said Neville A Mehra, Co-founder of Genki.

Genki World Resident includes health, vision, and dental coverage, as well as cover for prenatal care & childbirth, alternative treatments (such as homeopathy and osteopathy), chiropractic care, physiotherapy, and much more.

World Resident members can receive care at any locally-licensed healthcare provider in any country in the world, with no maximum benefit limit for medical treatment.

In addition, Genki World Resident comes with telemedicine access and a 24/7 emergency assistance hotline, who can arrange direct billing with any hospital.

For more information and early access visit: https://genki.world/insurance/world-resident

###

About Genki:

Genki is the startup focused on health for digital nomads. Genki’s mission is to help nomads be healthy and live well wherever they go. The German company has developed innovative international health insurance plans to support the growing community of digital nomads and nomad families. With Genki, digital nomads no longer have to choose between traveling the world and taking great care of their health.

Share article on social media or email:

Spaulding Academy & Family Services Adds Two to Leadership Team


Spaulding Academy & Family Services New Leadership Additions, Courtrney Constant and Nick Silva

Spaulding Academy & Family Services New Leadership Additions, Courtrney Constant and Nick Silva

“We are excited to welcome these young professionals to our leadership team and look forward to the contributions, passion and fresh perspectives these two individuals will undoubtedly bring to our experienced leadership team,’ said Todd Emmons, CEO, Spaulding Academy & Family Services.

Spaulding Academy & Family Services has named two new directors to their executive leadership team. Courtney Constant has joined as the organization’s Director of Development and Community Relations and Nick Silva was recently promoted to Director of Admissions.

Constant previously worked in real estate as Director of Operations at Lake Life Realty – Compass New England since 2018. In her role at Lake Life Realty, she led the agency’s team to raise over $200,000 for Make-A-Wish New Hampshire and continues to volunteer on the Rafting for Wishes event planning committee. Constant holds a master’s degree in Human Relations and a bachelor’s degree in Psychology from Plymouth State University.

Since joining Spaulding Academy & Family Services in 2014, Silva was successful in several roles across campus, including Academic Aide, Paraprofessional, Residential Counselor and Associate Teacher. This experience made him uniquely qualified to earn a promotion to Admissions Assistant in 2017. As the Admissions Assistant, he worked closely with each department on campus to lead tours, follow up on new student’s progress and be a part of the Spaulding enrollment process from start to finish. Silva holds an MBA from Southern New Hampshire University and a bachelor’s degree from Elms College.

“We are excited to welcome these young professionals to our leadership team and look forward to the contributions, passion and fresh perspectives these two individuals will undoubtedly bring to our experienced leadership team,” said Todd Emmons, Chief Executive Officer, Spaulding Academy & Family Services. “As an ever-evolving organization, Spaulding is continuously looking for opportunities to promote from within and demonstrate our campus-wide dedication to diversity.”

For more information regarding currently available positions, visit SpauldingServices.org/jobs.

ABOUT SPAULDING ACADEMY & FAMILY SERVICES

Spaulding Academy & Family Services is a leading provider of educational, residential, therapeutic and community-based programs and services for families, and children and youth with neurological, emotional, behavioral, learning or developmental challenges, including Autism Spectrum Disorder and those who have experienced significant trauma, abuse or neglect. Established in 1871 as the New Hampshire Orphans Home and School for Industry, Spaulding Academy & Family Services is the oldest child care organization in operation in the United States. It is a is a tax-exempt 501(c)(3) nonprofit that was formerly known as Spaulding Youth Center since 1958. Its scenic hilltop campus is located on over 500 acres in Northfield, NH and welcomes boys and girls from ages 4 to 22 from around the state of New Hampshire and beyond. In addition to programs provided on the Northfield campus, Spaulding’s community-based programs include foster family licensing, Individual Service Option (ISO) foster care, ISO in-home services, child health support services, and more for children ages 0 to 20 and their family. For information about Spaulding Academy & Family Services, visit http://www.SpauldingServices.org.

Share article on social media or email:

Dr. Cherag Daruwala of Hunterdon Gastroenterology Awarded As NJ Top Doc


Cherag Daruwala, MD

Cherag Daruwala, MD

Like many gastroenterologists, I enjoy the technological aspect of my specialty. However, I am also receptive to patients who prefer a more holistic approach to treatment.

NJ Top Docs has reviewed and approved Dr. Cherag Daruwala of Hunterdon Gastroenterology Associates for 2022. This is Dr. Daruwala’s seventh consecutive year being reviewed and approved by NJ Top Docs. Dr. Daruwala is a board certified Gastroenterologist and Hepatologist.

After completing his fellowship in Gastroenterology, Dr. Daruwala went on to complete training in endoscopic ultrasound and was on staff at Temple University Hospital for 3 years prior to joining Hunterdon Gastroenterology Associates in 2012. Dr. Daruwala established the endoscopic ultrasound program at Hunterdon Medical Center.

“Like many gastroenterologists, I enjoy the technological aspect of my specialty. However, I am also receptive to patients who prefer a more holistic approach to treatment,” says Dr. Daruwala.

Dr Daruwala is among the first gastroenterologists to offer Endoscopic Ultrasound in Central New Jersey. This procedure offers an accurate and less invasive method for the diagnosis and staging of various cancers. In addition to Endoscopic ultrasound, he has a keen interest in colon cancer screening as well as the management of acid reflux disease, hepatitis and irritable bowel syndrome. He has offices in Flemington and Somerville, New Jersey.

To learn more about Dr. Cherag Daruwala, please visit: https://njtopdocs.com/nj-doctors/daruwala/

About Us

NJ Top Docs is a comprehensive, trusted and exclusive healthcare resource featuring reviewed and approved Top Doctors and Dentists in New Jersey online in an easy to use format. NJ Top Docs only reviews and approves providers based on merit after they have been extensively vetted.

NJ Top Docs is a division of USA Top Docs which allows patients to meet providers online before making their appointment. For more information, please click here to contact us or visit http://www.NJTopDocs.com.

You can also follow us on Facebook, Twitter, & Instagram.

Share article on social media or email:



Sidestepping “The Talk” – New study explores the motives and consequences of avoiding those awkward yet necessary conversations


Trying to avoid awkward conversations only hurts us in the long-run.

Sidestepping that awkward conversation with your friend, partner, family member, or boss won’t do you any good in the long-run.

When we try to avoid something, it will usually continue to rear its head until we are forced to face it.

Parents giving the “birds and the bees” talk. Romantic partners wanting to know where the relationship is going. Confronting a jerk at work or having to apologize for being the jerk. Life is filled with conversations most people don’t want to have, but avoidance has consequences. Based on a study by PsychTests.com, the short-term respite of dodging that awkward talk can lead to long-term social and psychological repercussions.

Analyzing data collected from 12,259 people who took the Emotional Intelligence Test, PsychTests’ researchers compared the personality profile of two distinct groups: people who tend to avoid awkward conversations (“Avoiders”) and those who don’t (“Non-Avoiders”). Here’s what the results revealed:

AVOIDERS DON’T JUST DODGE AWKWARD CONVERSATIONS – THEY HAVE A TENDENCY TO EVADE ANYTHING THEY FIND UNPLEASANT.

> 52% of Avoiders are uncomfortable showing their emotions (vs. 21% of Non-Avoiders).

> 62% don’t like talking about their feelings (vs. 15% of Non-Avoiders).

> 53% feel awkward expressing affection or appreciation (vs. 11% of Non-Avoiders).

> 56% will actually suppress their own negative emotions rather than face them (vs. 32% of Non-Avoiders).

> 69% dodge confrontation (vs. 18% of Non-Avoiders).

> 77% won’t ask for what they want – a raise in salary, for example – even when they really desire it or feel they deserve it (vs. 20% of Non-Avoiders).

> 55% are too self-conscious to ask questions if they don’t understand something (vs. 10% of Non-Avoiders).

> 59% get tongue-tied talking to authority figures (vs. 12% of Non-Avoiders).

> 43% won’t correct their teacher or boss when he/she makes a mistake (vs. 25% of Non-Avoiders).

> 41% refrain from giving people advice for fear of steering them in the wrong direction (vs. 10% of Non-Avoiders).

According to PsychTests researchers, their study pointed to some potential motives for Avoiders’ tendency to sidestep awkward conversations, among other things they find disagreeable:

> 76% of Avoiders lack the willpower to push themselves to do things they don’t like (vs. 24% of Non-Avoiders).

> 75% feel like a “fish out of water” in most social situations (vs. 31% of Non-Avoiders).

> 46% are intimidated by anyone with a strong personality (vs. 11% of Non-Avoiders).

> 49% said that they have no idea how to deal with someone who is upset (vs. 9% of Non-Avoiders).

> 57% will hold back from expressing their ideas or opinions if there is a chance they may be mocked or ridiculed (vs. 11% of Non-Avoiders).

> 62% have a desperate need to be liked by everyone (vs. 30% of Non-Avoiders).

POTENTIAL CONSEQUENCES OF AVOIDANCE, ACCORDING TO PSYCHTESTS’ STUDY:

> 50% of Avoiders experience frequent emotional ups and downs (vs. 19% of Non-Avoiders).

> 60% frequently put other people’s needs ahead of their own, even when it leaves them feeling sad, upset, or resentful (vs. 37% of Non-Avoiders).

> 52% will pretend to agree with someone’s opinion in order to avoid a fight (vs. 16% of Non-Avoiders).

> 57% will spend hours analyzing and dissecting a person’s comments rather than just asking what he/she meant, or confronting someone who has hurt their feelings (vs. 21% of Non-Avoiders).

> 57% will apologize even when they know they haven’t done anything wrong (vs. 32% of Non-Avoiders).

> 33% of Avoiders are currently undergoing therapy for depression or suspect that they might be depressed (vs. 13% of Non-Avoiders).

> 33% of Avoiders are currently undergoing therapy for an anxiety disorder or suspect that they might have anxiety issues (vs. 18% of Non-Avoiders).

“You can probably avoid some unpleasant conversations but you can’t run from them forever. When we try to avoid something, it will usually continue to rear its head until we are forced to face it,” explains Dr. Ilona Jerabek, president of PsychTests. “People often try to avoid awkward conversations for fear of embarrassment or emotional pain. For example, we might decide not to bring up a problem, no matter how miserable it makes us, because we’re afraid that it could result in a relationship-ending fight or getting fired at work. In fact, 14% of the Avoiders in our study said that they’d rather walk away from a fight or let the other person win, compared to 6% of Non-Avoiders. The reality is that very often, those unpleasant conversations are necessary, and in the long-run, it will be far more difficult to live with a problem than to face it and talk about it. As we have seen in our study, avoidance leaves people feeling unhappy and unfulfilled.”

“For those who tend to sidestep sensitive conversations, my advice would be to face the unpleasantness head-on. Write down exactly what you want to say, and if possible, bring someone for emotional support. Practice saying it to get more comfortable with the message. Learn about assertiveness techniques, and ideally find a coach who can help you practice. Keep in mind that even the most difficult discussions can happen calmly and with a positive tone if you can deliver the message assertively, but with empathy . Most importantly, think about all the consequences of not speaking up. If they outweigh the repercussions of avoidance, then take it as a sign that this is a conversation you need to have.”

What’s your EQ? Check out the Emotional Intelligence Test at https://testyourself.psychtests.com/testid/3979

Professional users, such as HR managers, coaches, and therapists, can request a free demo for this or other assessments from ARCH Profile’s extensive battery: http://hrtests.archprofile.com/testdrive_gen_1

To learn more about psychological testing, download this free eBook: http://hrtests.archprofile.com/personality-tests-in-hr

About PsychTests AIM Inc.

PsychTests AIM Inc. originally appeared on the internet scene in 1996. Since its inception, it has become a pre-eminent provider of psychological assessment products and services to human resource personnel, therapists and coaches, academics, researchers and a host of other professionals around the world. PsychTests AIM Inc. staff is comprised of a dedicated team of psychologists, test developers, researchers, statisticians, writers, and artificial intelligence experts (see ARCHProfile.com).

Share article on social media or email:

NeuroCytonix Completes Clinical Trial of its NeuroCytotron Treatment of Cerebral Palsy


NeuroCytonix Logo

NeuroCytonix Completes Clinical Trial of its NeuroCytotron Treatment of Cerebral Palsy

NeuroCytonix, Inc. (the “Company” or “NeuroCytonix”) today announced that on January 19, 2023, its subsidiary NeuroCytonix Mexico has received a regulatory acknowledgment letter from the Mexican regulatory authority COFEPRIS – ref/memorandum number 223300ES450795/2023 – following the presentation of NeuroCytonix final report on its clinical trial on Cerebral Palsy NCX-CP-01.

The acknowledgment represents the legal and formal conclusion of the clinical trial, according to the methodology authorized by COFEPRIS. The resolution of the NCX-CP-01 clinical trial provides safety and efficacy data on investigational NeuroCytotron treatment of Cerebral Palsy. A manuscript detailing the results of this clinical trial is currently under preparation and will soon be submitted to several scientific journals.

The results of this clinical trial provide support for additional studies that will continue to evaluate the ongoing application of therapies with the NeuroCytotron in larger groups of patients, which will be supported by a Standard Operating Procedure where all cases will be recorded. This acknowledgment confirms that NeuroCytonix is ​​a company that has formally concluded a clinical trial for its investigational NeuroCytotron treatment and is now registered in the National Registry of Research Companies in Mexico.

About NeuroCytonix

NeuroCytonix is an emerging biotechnology business founded in January 2017 to develop and exploit transformational medical technologies for the regeneration of the nervous system. The Company’s technology and related protocols include Stroke, Autism, Cerebral Palsy and neurological consequences of Traumatic Brain Injury (TBI) and Covid19. The Company’s core technology, the NEUROCYTOTRON, utilizes non-invasive, safe, tissue engineering technology that stimulates proteins which aid in the regeneration of brain cells.

The NeuroCytonix technology is based on the work of its founder and CEO, Dr. J. Roberto Trujillo, an MD and PhD from Harvard University who has been a leader in clinical and basic neuroscience research for brain regeneration technology for the past 25 years. Dr. Trujillo has devoted his career to pioneering regenerative medicine technologies with the hope of transforming the status quo of healthcare for these previously believed incurable conditions.

NeuroCytonix has built a Research Center in Monterrey Mexico where it has trained and directed a clinical research team who has successfully implemented its first Cerebral Palsy clinical trial evaluating the safety and efficacy of the treatment.

Link to the full study on ClinticalTrials.gov.

Please visit http://www.neurocytonix.com for more information.

Contact:

Laurent Lavigne du Cadet

Chief Financial Officer

llavigne@neurocytonix.com

Share article on social media or email:

Texere Publishing Fully Commits to Humanity’s Fight Against Infectious Diseases with the Launch of ID Transmission


Texere Publishing Fully Commits to Humanity’s Fight Against Infectious Diseases with the Launch of ID Transmission

“ID Transmission truly sets the bar as a reactive, authentic, and innovative source of information. Our aim is to be the central hub – unifying and connecting everyone working in the field of infectious diseases around the world”: Frank Stoll, Publisher of ID Transmission

Texere Publishing today announces the launch of ID Transmission – a media brand dedicated to exploring humanity’s ongoing battle against infectious diseases.

Focusing on four key areas – understanding, testing, treating, and preventing – ID Transmission will bring the latest updates to healthcare and life science professionals working across the clinical, industrial, and academic spaces.

Since 2012, Texere has prided itself in bringing a unique approach to scientific and healthcare media. Today, Texere further extends its reach with a brand that offers a creative yet authoritative perspective on the field of infectious diseases.

As the world emerges from the COVID-19 pandemic, healthcare professionals, organizations, governments, and the general public are realizing that the next threat is likely just around the corner. ID Transmission explores the emerging science of infectious diseases, the technologies, and the people behind them.

Frank Stoll, Publisher of ID Transmission, said, “ID Transmission truly sets the bar as a reactive, authentic, and innovative source of information. Our aim is to be the central hub – unifying and connecting everyone working in the field of infectious diseases around the world.”

Liv Gaskill, Editor of ID Transmission, commented, “It’s an exciting time to be covering infectious diseases. There seems to have been a light cast upon the field by COVID-19, which isn’t going to dim anytime soon – and we’ll be there reporting on it at every turn.”

Andy Davies, CEO at Texere, added, “Hot on the heels of our December 2022 launch of The New Optometrist, we are delighted to announce another exciting brand – one that straddles our Healthcare, Pharmaceutical, and Science sectors. ID Transmission ramps up our coverage of infectious diseases – inarguably, a highly important field. With Frank Stoll and Editor Liv Gaskill at the helm, I expect great things!”

You can find out more about ID Transmission by visiting the Texere Publishing website where you can also watch a short video providing more detail about the new brand.

You can also visit the newly launched ID Transmission website here and register to the weekly newsletter here.

ENDS

About Texere Publishing

At Texere Publishing, we deliver fearless, compelling, behind the scenes stories that matter in the life sciences and medicine. Our unrivaled access to key opinion leaders, influencers, scientists, and doctors who are making a difference, means that our readers are connected to the pulse of their fields. Founded in 2012, we have expanded our editorial beat to the world with our presence in the US, Canada, and the UK. Visionary. Innovative. Fearless.

Publishers of The Analytical Scientist, The Cannabis Scientist, The Medicine Maker, The New Optometrist, The Ophthalmologist, The Pathologist, The Translational Scientist, and ID Transmission.

texerepublishing.com | Twitter | LinkedIn | Instagram | Facebook

Share article on social media or email: